Accelerated immunosenescence in SLE: current evidence and clinical translation - Takeaways - MDSpire

Accelerated immunosenescence in SLE: current evidence and clinical translation

  • By

  • Qingshuang Li

  • Wei Zhang

  • Yulan Chen

  • Jing Du

  • June 17, 2026

  • 0 min

Share

  • 1

    Systemic lupus erythematosus (SLE) exhibits accelerated immunosenescence, leading to age-related health issues in younger patients.

  • 2

    SLE is associated with increased risks of cardiovascular disease, frailty, cognitive impairment, and reduced vaccine responsiveness.

  • 3

    Premature expansion of senescent-like immune cell subsets contributes to the immune dysfunction observed in SLE patients.

  • 4

    Immunosenescence in SLE can be quantified using immunophenotyping and epigenetic clocks, aiding in risk stratification and treatment decisions.

  • 5

    Current immune-aging measures in SLE are candidate research biomarkers, necessitating further studies to validate their clinical utility.

Original Source(s)

Accelerated immunosenescence in SLE: current evidence and clinical translation

  • by Qingshuang Li, Wei Zhang, Yulan Chen, Jing Du

  • June 17, 2026

Related Content

Serum uric acid in systemic lupus erythematosus with preserved renal function: a cross-sectional and longitudinal analysis

Correction: Clinical significance of erythrocyte sedimentation rate-based stratification in a large retrospective SLE cohort

Clinical characteristics and risk factors of protein-losing enteropathy: a retrospective study